1. Home
  2. PRAX vs MORN Comparison

PRAX vs MORN Comparison

Compare PRAX & MORN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$337.29

Market Cap

9.0B

Sector

Health Care

ML Signal

HOLD

Logo Morningstar Inc.

MORN

Morningstar Inc.

HOLD

Current Price

$167.00

Market Cap

8.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
MORN
Founded
2015
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
8.8B
IPO Year
2020
2004

Fundamental Metrics

Financial Performance
Metric
PRAX
MORN
Price
$337.29
$167.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
2
Target Price
$572.13
$256.50
AVG Volume (30 Days)
326.2K
473.0K
Earning Date
05-08-2026
04-29-2026
Dividend Yield
N/A
1.07%
EPS Growth
N/A
3.38
EPS
N/A
2.73
Revenue
N/A
$2,445,500,000.00
Revenue This Year
N/A
$9.14
Revenue Next Year
$7,758.26
$7.23
P/E Ratio
N/A
$61.71
Revenue Growth
N/A
7.49
52 Week Low
$34.89
$149.08
52 Week High
$354.87
$316.71

Technical Indicators

Market Signals
Indicator
PRAX
MORN
Relative Strength Index (RSI) 55.91 41.16
Support Level $282.49 $165.70
Resistance Level $353.83 $190.99
Average True Range (ATR) 18.75 7.03
MACD -0.96 -1.44
Stochastic Oscillator 69.67 3.96

Price Performance

Historical Comparison
PRAX
MORN

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About MORN Morningstar Inc.

Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.

Share on Social Networks: